Paraplatin

Carboplatin

Advanced ovarian carcinoma of epithelial origin as 1st-line therapy; or 2nd-line therapy after failed treatment w/ other chemotherapeutic agents. Small cell carcinoma of the lung & squamous cell carcinoma of the head & neck.

Previously untreated adult w/ normal renal function 400 mg/m² as a single dose administered by slow IV infusion (15-60 min). Do not repeat therapy until 4 wk have elapsed &/or until neutrophil count is at least 2,000/mm³ & platelet count is at least 100,000/mm³. Patient w/ renal impairment Initial dose: CrCl 41-59 mL/min 250 mg/m² IV on day 1, CrCl 16-40 mL/min 200 mg/m² IV on day 1. Subsequent dose: Adjust according to patient's tolerance & desired myelosuppressive effect.

Hypersensitivity to carboplatin or other platinum-containing prep. Severe myelosuppression. Tumor bleedings. Marked hearing impairment. Severe renal (existing or diagnosed earlier) &/or severe hepatic impairment. Pregnancy & lactation.

Very hemotoxic. Do not administer by rapid IV inj. Regularly perform full blood counts, tests of kidney & liver function, as well as checks of neurologic status. Discontinue treatment in case of marked myelosuppression or severe renal or hepatic disorders. Reports of posterior reversible encephalopathy syndrome, in most cases as part of combined chemotherapy. Optimal use in combination w/ other myelosuppressive drugs requires dose adjustments according to the polychemotherapy regimen adopted. Risk of more pronounced myelosuppression in patients w/ renal insufficiency, in patients who have received an intensive myelosuppressive treatment or cisplatin, as well as in persons w/ impaired general state of health. Reports of hemolytic anemia w/ existing drug-induced serological Abs. Consider serological testing & treatment discontinuation in case of unexplained hemolysis. Reports of auditory defects during therapy. Reports concerning early hyponatremia. Inj site reactions may occur during administration. Avoid use of live vaccines; nephrotoxic &/or ototoxic medications. May impair ability to drive or operate machinery. Effective contraception is required for both male & female patients during treatment & up to 6 mth after ending treatment. May decrease male fertility. Elderly.

Anemia, thrombopenia, leukopenia, neutropenia; diminished serum levels of Na, K, Ca, Mg; abdominal pain, nausea, vomiting; increased SGOT & alkaline phosphatase; decreased CrCl. Infectious complications (sometimes lethal); haemorrhages (sometimes lethal); allergic reactions eg, exanthema, urticaria, erythema, fever w/o detectable cause, itching, anaphylactic reactions w/ bronchospasms & hypotension at treatment initiation; central nervous symptoms, peripheral neuropathy including paresthesias & weakness of tendon reflexes, peripheral sensory disturbances eg, visual disorders, taste impairment; ototoxicity; CV disturbances; dyspnoea, increased cough, pulmonary toxicity; diarrhoea, constipation, mucositis; increased bilirubin; skin reactions/changes, alopecia; increased uric acid, urinary incontinence, dysuria, increased urinary frequency, nocturia; asthenia.

Potentiation of myelotoxicity w/ myelosuppressive substances. Cumulative nephrotoxicity & ototoxicity w/ aminoglycosides; loop diuretics; other nephrotoxic &/or ototoxic medications. Increased risk of fatal systemic vaccine disease w/ live vaccines.

Cytotoxic Chemotherapy

L01XA02 - carboplatin ; Belongs to the class of platinum-containing antineoplastic agents. Used in the treatment of cancer.

P₁S₁S₃